Purpose: In this study, we examined the promoter methylation status and expression of 14-3-3 and evaluated its clinical significance in epithelial ovarian cancer.
INTRODUCTION
Epithelial ovarian cancer is the leading cause of death from gynecological malignancies in the great majority of developed countries (1) . This high mortality is considered to be, in large part, due to the advanced stage of the disease commonly present at the time of diagnosis, but many clinical studies have reported that there are some prognostic factors in ovarian cancer other than clinical stages, such as histology, the degree of primary surgical cytoreduction, and response to chemotherapy (1) (2) (3) . Other prognostic parameters have been also proposed in addition to those relatively established parameters. These include Ki67 index, progesterone receptor, and the preoperative serum maker CA125, and others (4 -6) . The identification of new prognostic factors may further contribute to improve treatment and clinical outcome of ovarian cancer patients.
The cause of epithelial ovarian cancer is still unknown. Although BRCA1 and BRCA2 mutation have been identified as associated with susceptibility to ovarian cancer (7, 8) , mutations in these genes account for only 2-3% of all ovarian cancers. The remaining cases are considered to be sporadic in nature and arise as a result of acquired alterations in oncogenes and tumor suppressor genes such as TP53 and PTEN (9 -11) .
DNA methylation has an essential regulatory function in mammalian development, suppressing gene activity by changing chromatin structure (12, 13) . It has become apparent that aberrant DNA methylation of promoter region CpG islands may serve as an alternate mechanism to genetic defects in the inactivation of tumor suppressor genes in human cancers (14, 15) . Accordingly, the identification of gene targets of methylationassociated silencing could lead to novel genes involved in the initiation and progression of human neoplasia.
14-3-3 was originally identified as a p53-inducible gene that is responsive to DNA damaging agents (16) . Recent study demonstrated that 14-3-3 protein plays a crucial role in the G 2 checkpoint by sequestering the mitotic initiation complex, cdc2-cyclin B1, in the cytoplasm after DNA damage (17) . This prevents cdc2-cyclin B1 from entering the nucleus in which the protein complex would normally initiate mitosis. In this manner, 14-3-3 induces G 2 arrest and allows the repair of damaged DNA (16, 17) . The expression of 14-3-3 is reported to be frequently lost in human breast, gastric, and lung cancers, and the inactivation is due to aberrant DNA methylation (18 -20) . However, the expression of 14-3-3 and its mechanism have not been examined in epithelial ovarian cancer. Therefore, in this study, we examined the promoter methylation status and expression of 14-3-3 in epithelial ovarian cancer cells. We also evaluated the correlation between 14-3-3 expression and clinicopathological parameters in patients with epithelial ovarian cancer.
MATERIALS AND METHODS
Tissues and Cells. Eight normal ovaries, 8 ovarian serous cystadenomas, 12 serous borderline tumors, and 102 ovarian cancer cases were obtained from patients after surgical therapy from 1988 to 2000 at Tohoku University Hospital, Sendai, Japan. In ovarian cancer patients, information regarding age, performance status on admission, histology, stage, grade, residual tumor after primary surgery, and overall survival were retrieved from the review of patient charts. Median follow-up time of the patients in this study was 59 months (4 -120 months). Eighty-four (82.3%) of 102 patients received platinum-containing chemotherapy after operation. Patients who have early-stage (stage Ia) and low grade-disease (G1, G2) and patients who have poor performance status did not receive platinum-based chemotherapy. Performance status was defined according to WHO criteria (21) . Histology and stage were determined according to FIGO (International Federation of Gynecology and Obstetrics) criteria. Grade was evaluated by one of the authors (T. M.) using universal grading system in epithelial ovarian cancer (22) . Residual disease was determined by the amount of unresectable tumor that remained after primary cytoreductive surgery. Optimal cytoreduction was defined as no gross residual tumor greater than 2 cm in diameter, and suboptimal cytoreduction was defined as any gross residual disease remaining greater than 2 cm in diameter. Overall survival was calculated from the time of initial surgery to death, or the date of last contact. Survival times of patients still alive or lost to follow-up were censored in December 2002. All of these archival specimens were retrieved from the surgical pathology files at Tohoku University Hospital, Sendai, Japan. These specimens were all fixed in 10% formalin and embedded in paraffin. The research protocol was approved by the ethics committee of Tohoku University Graduate School of Medicine.
OVCAR3, Caov3, SKOV3, TOV112D, TOV21G, OV90, and ES2 (adenocarcinoma, OVCAR3, SKOV3; serous adenocarcinoma, Caov3, OV90; clear cell adenocarcinoma, TOV21G, ES2; endometrioid adenocarcinoma, TOV112D) cell lines were purchased from American Type Culture Collection. JHOS2, JHOS3, HTOA, OMC3, and JHOC5 (serous adenocarcinoma, JHOS2, JHOS3, HTOA; mucinous adenocarcinoma, OMC3; clear cell adenocarcinoma, JHOC5) cell lines were purchased from Riken cell bank (Tsukuba, Japan). Normal ovarian surface epithelial cell lines (OSE2 and OSE4) were established by one of the authors (M. N.; Ref. 23) . Cell lines were maintained in DMEM/F12 (Invitrogen) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen), and were incubated in 5% CO 2 at 37°C. For 5-aza-2Ј deoxycytidine (5azaC) treatment, 1 ϫ 10 6 cells were seeded into T75 flasks and were treated with 0.5 M or 1.0 M 5azaC (Sigma) for 72 h.
Methylation-Specific PCR. Methylation status of the samples was investigated by methylation-specific PCR as described in the literature (24) . Genomic DNA of ovarian cancer tissue was extracted using a laser capture microdissection and treated with proteinase K (0.5 mg/ml) for 48 h at 37°C. Genomic DNA from ovarian cancer cell lines was extracted using AquaPure Genomic DNA kit (Bio-Rad). The quality and integrity of the DNA was determined by the A260:280 ratio. One g of genomic DNA was treated with sodium bisulfite using CpGenome DNA modification kit (Intergen) according to the instructions. Amplification was achieved in a 20-l reaction volume containing 2 l of 10ϫ Ex Taq Buffer, 1.5 l of 25 mM MgCl 2 , 1 M each primer, 1.5 l of 2.5 mM dNTPs, and 1 unit of Takara Ex Taq polymerase (Takara, Japan). Hot-start PCR was performed in a thermal cycler (Takara) for 35 cycles, each of which consisted of denaturation at 96°C for 30 s, annealing at 64°C for 30 s, and extension at 72°C for 90 s, followed by a final 10 min extension at 72°C. Primers used were 5Ј-TGGTAG-TTTTTATGAAAGGCGTC-3Ј and 5Ј-CCTCTAACCGCCCA-CCACG-3Ј (104-bp) for the methylated reaction (M primers), and 5Ј-ATGGTAGTTTTTATGAAAGGTGTT-3Ј and 5Ј-CCCT-CTAACCACCCACCACA-3Ј (106-bp) for the unmethylated reaction (U primers; Ref. 18 ). Universal methylated human male genomic DNA (Intergen) was used as a positive control for methylated reaction. Genomic DNA purified from MCF-7 breast cancer cell line was used as a positive control for unmethylated reaction (18) . A blank control containing all of the PCR components except template DNA was also included in all of the PCRs. Reaction products were separated by electrophoresis on a 3% agarose gel, stained with ethidium bromide, and visualized under UV illumination. Specimens with purely unmethylated promoters have positive PCR products by U primers but not with the M primers. Specimens that contain purely methylated promoters will have PCR products by using M primers but not with the U primers. Specimens that contain heterogeneous status of both methylated and unmethylated promoters have PCR products from both U primers and M primers.
Reverse Transcription and Real-Time Quantitative PCR. Total RNA was isolated from cell lines by phenolchloroform extraction using Isogen (Nippon Gene, Tokyo, Japan). RNA was treated with RNase-free DNase (Roche Diagnostics; 1 g/l) for 2 h at 37°C, followed by heat inactivation at 65°C for 10 min. A reverse transcription-PCR kit (SUPER-SCRIPT II First-strand synthesis system, Invitrogen) was used and cDNA synthesis was carried out according to the instructions. cDNAs were synthesized from 2 g of total RNA using random hexamer, and reverse transcription was carried out for 50 min at 42°C with SUPERSCRIPT II reverse transcriptase. Real-time quantitative PCR was performed using the iCycler system (Bio-Rad). For the determination of 14-3-3 cDNA content, a 25-l reaction mixture consisted of 23 l iQ SYBR Green MasterMix, 1 M each primer, and 1 l of template cDNA were prepared. The PCR conditions were as follows: initial duration at 96°C for 60 s, and followed by 35 cycles with denaturation at 96°C for 30 s, annealing at 64°C (both for 14-3-3 and ␤-actin) for 30 s, and extension at 72 o C for 30 s. The fluorescence intensity of the double-strand specific SYBR Green I, reflecting the amount of formed PCR-product, was read at 88°C after the end of each elongation step. Primers used were as follows: 14-3-3, 5Ј-CCTGCTGGACAGCCACCTCA-3Ј and 5Ј-TGTCGGCCGTCCACAGTGTC-3Ј (397-bp; Ref. 20); ␤-actin, 5Ј-CCAACCGCGAGAAGATGA-3Ј and 5Ј-GGAAG-GAAGGCTGGAAGAGT-3Ј (459-bp; Ref. 25) . ␤-actin cDNA fragments were amplified as internal positive controls. Normal human ovarian cDNA library (Stratagene, La Jolla, CA) was used as a normal control, cDNA from MCF-7 was used as a positive control, and water blank was used as a negative PCR control (data not shown). Control reactions in which reverse transcriptase was omitted were amplified under the same conditions to exclude DNA contamination (data not shown). Two independent quantitative PCR reactions were performed for each sample.
Immunohistochemistry. Immunohistochemical analysis was performed using the streptavidin-biotin amplification method using a Histofine kit (Nichirei, Tokyo, Japan), and have been previously described in detail (26) . Polyclonal antibody for 14-3-3 (N-14), monoclonal antibody for p53 (B20.1), and monoclonal antibody for Ki-67 (MIB-1) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), Biomeda (Foster City, CA), and DAKO (Tokyo, Japan), respectively.
For antigen retrieval, the slides were heated in an autoclave at 120°C for 5 min in citric acid buffer [2 mM citric acid and 9 mM trisodium citrate dyhydrate (pH 6.0)]. The dilutions of primary antibodies for 14-3-3, p53 and Ki-67 were 1:100, 1:40, and 1:300, respectively. The antigen-antibody complex was visualized with 3,3Ј-diaminobenzidine (DAB) solution [1 mM DAB, 50 mM TrisHCl buffer (pH 7.6), and 0.006% H 2 O 2 ], and counterstained with hematoxylin. Nonneoplastic breast epithelial tissue was used as a positive control (18) . As negative controls, 0.01 M PBS and normal mouse IgG were used in place of primary antibodies.
The immunohistochemical expression of 14-3-3, p53, and Ki-67 was independently reviewed by two of the authors (J. A. and T. M.) who had no knowledge of the clinicopathological data. As immunoreactivities of 14-3-3 and p53 were relatively homogeneous and clearly distinguished for positive and negative, they were classified into two groups: ϩ, positive carcinoma cells; and Ϫ, no immunoreactivity. Scoring of Ki-67 in carcinoma cells was counted independently by these same two authors, and the percentage of immunoreactivity in at least 500 carcinoma cells, i.e., labeling index, was determined. Whenever a difference of greater than 5% was observed between the two readings, slides were reviewed jointly, and a consensus was reached.
Statistical Analysis. Statistical analysis was performed using Stat View 5.0 (SAS Institute Inc.) software. The statistical significance between 14-3-3 and characteristics of the patients was evaluated using Mann-Whitney U test, Kruskal-Wallis test, and Scheffe analysis. Correlation between 14-3-3 and Ki-67, p53 immunoreactivity was also assessed using Mann-Whitney U test. Univariate analysis of prognostic significance for prognostic factors was performed using a log-rank test, after each survival curve was obtained by the Kaplan-Meier method. Multivariate analysis was performed using Cox regression model to evaluate the predictive power of each variable independently of the others. All of the patients who could be assessed were included in the intention-to-treat analysis. A result was considered significant when the P was less than 0.05.
RESULTS
Methylation Status and Expression of 14-3-3 in Ovarian Cancer Cells. Among the 12 ovarian cancer cell lines in which 14-3-3 promoter methylation was investigated, the presence of a methylated band was detected in 7 cell lines, 2 of which were together with unmethylated band as shown in Fig. 1 . The methylated band was detected in all of the cell lines derived from clear cell adenocarcinoma (TOV21G, ES2, JHOC5), two of five of serous adenocarcinoma (Caov3, OV90, JHOS2, JHOS3, HTOA), one of one of endometrioid adenocarcinoma (TOV112D), and none of one of mucinous adenocarcinoma (OMC-3). Both of the OSE cells were negative for methylated band.
The expression of 14-3-3 gene is shown in Fig. 2A . Quantitative reverse transcription-PCR was performed and the ratio of 14-3-3:␤-actin was calculated to allow for comparison between the cell lines. Median values of relative 14-3-3 gene expression in cancers with methylation (3.27) were significantly lower than those without methylation (16.4; P Ͻ 0.001, Kruskal-Wallis test). In HTOA, the expression of 14-3-3 gene was relatively decreased, although this cell line did not have methylated promoter alleles. The expression of 14-3-3 gene was relatively high in OSE2 (8.6), OSE4 (16.2), and in the normal ovarian cDNA library (10.8).
To further confirm that aberrant DNA methylation contributed to loss of expression of 14-3-3 gene, we assessed the effect of 5azaC, a demethylating agent, on 14-3-3 mRNA expression by quantitative reverse transcription-PCR. Treatment of OVCAR3 and OV90 cells with 5azaC for 3 days resulted in the complete and partial demethylation of the promoter CpG islands and reexpression of 14-3-3 gene, respectively (Fig.  2B) . The amount of expression of mRNA after treatment (14.9 and 5.8 for 0.5 M, and 18.4 and 4.9 for 1.0 M in OVCAR and OV90, respectively) was significantly higher than that before . The decreased expression of 14-3-3 in this cell line is, therefore, not attributable to abnormalities at the gene level or to the inability to express 14-3-3, but rather is directly related to the methylation.
Immunohistochemistry and Methylation Status of 14-3-3 in Ovarian Cancer Tissues. Positive immunoreactivity for 14-3-3 was detected in the cytoplasm of epithelial cells, although p53 and Ki-67 were confined exclusively to the nuclei of epithelial cells (Fig. 3) . In normal, benign, and borderline tissues, all of the cases were positive for 14-3-3 immunoreactivity. In ovarian cancer tissues, 73.5% (75 of 102) and 36.3% (37 of 102) were positive for 14-3-3 and p53, respectively. Median Ki-67 labeling index was 17.2%.
To further clarify the relationships between 14-3-3 immunoreactivity and aberrant DNA methylation in ovarian cancer tissues, we analyzed the methylation status in microdissected ovarian cancer tissues (Fig. 4) . In the 10 cases of positive immunoreactivity, unmethylated bands were detected in all of the cases, and methylated bands were detected in 3 cases. In the another 10 cases of negative immunoreactivity, methylated bands were detected in 8 cases, although only unmethylated bands were detected in 2 cases.
Correlation between Clinicopathological Parameters and Immunohistochemistry in Ovarian Cancer Patients.
Results of immunohistochemistry for 14-3-3, p53, and Ki-67 and correlation with clinicopathological parameters are summarized in Table 1 . Negativity of 14-3-3 was significantly correlated with high age, serous histology, high-grade, advancedstage, residual tumor of Ͼ2 cm, high serum CA125, and high Ki-67 labeling index. Interestingly, p53 expression was inversely correlated with that of 14-3-3.
Results of univariate analysis of prognostic significance for a Performance status score: 0, asymptomatic and fully active; 1, symptomatic, fully ambulatory, restricted in physically strenuous activity; 2, symptomatic, ambulatory, capable of self-care, more than 50% of waking hours are spent out of bed; 3, symptomatic, limited self-care, spends more than 50% of time in bed, but not bedridden; 4, completely disabled, no self-care, bedridden.
b Residual tumor is defined in the "Materials and Methods." c LI, labeling index.
each variable with respect to survival are summarized in Table  2 . In this analysis, we determined the positive cases of Ki-67 as those with a labeling index of more than 15%. Among the clinicopathological factors examined, those significantly associated with overall survival were 14-3-3 immunoreactivity, age, performance status, grade, stage, residual tumor, and Ki-67. Negative 14-3-3 cases had significantly worse overall survival rates than positive cases ( Fig. 5 ; P ϭ 0.0058). In multivariate analysis, 14-3-3 immunoreactivity turned out not to be an independent prognostic indicator ( Table 3) . Among the variables examined, only stage and residual tumor turned out to be independent prognostic factors.
DISCUSSION
The aberrant methylation of 14-3-3 was associated with loss of RNA expression, and the expression was restored by treatment with the demethylating agent 5azaC, indicating that aberrant DNA methylation is the main pathway of transcriptional silencing of 14-3-3 gene in ovarian cancer cells. Also, decreased expression of 14-3-3 occurs in substantial proportion, and it turned out to be a prognostic factor in univariate analysis in epithelial ovarian cancer tissues. These results suggest the importance of the 14-3-3 gene in the development and progression of this tumor. To our knowledge, this is the first report on epigenetic silencing of 14-3-3 in human ovarian cancer.
The 14-3-3 gene is demonstrated to be induced after DNA damage in a p53-dependent manner (16) , and to play a role in the G 2 checkpoint by sequestering the Cdc2/cyclin B1 complex (17) . Similar to our results, several authors demonstrated epigenetic inactivation of the 14-3-3 gene in human cancers (18, 20, 27) . Experimental inactivation of the 14-3-3 gene causes a G 2 checkpoint defect, and results in the accumulation of chromosomal aberrations that increase the sensitivity to the DNAdamaging events (28, 29) . In this context, it is of interest that serous histology in which significantly decreased expression of 14-3-3 protein was observed is highly sensitive to chemotherapeutic agents. The histological type-specific expression of the 14-3-3 gene suggests that serous adenocarcinomas develop unique differentiation, different from other histological subtypes. Although a high proportion of human cancers are likely to have a chromosomal instability phenotype, mutations of the genes involving the G 2 -M-phase checkpoint have rarely been found, and the mechanism of chromosomal instability in most of them is still unknown. Further study on the correlation between genetic instability and 14-3-3 is needed.
In a number of previous reports, it is strongly postulated that the inactivation of 14-3-3 might play an important role in tumor progression. Ostergaard et al. (30) showed that less-differentiated bladder squamous cell carcinoma is characterized by decreased expression of some proteins, including 14-3-3. Suzuki et al. (19) reported that aberrant methylation of the 14-3-3 gene was frequently observed in poorly differentiated gastric adenocarcinoma. Umbricht et al. (31) reported that decreased expression of 14-3-3 was observed in 24 (96%) of 25 carcinomas, 15 (83%) of 18 of ductal carcinoma in situ, and 3 (38%) of 8 of atypical hyperplasias, and concluded that inactivation of 14-3-3-sigma occurs at an early stage in the progression of invasive breast cancer. Osada et al. (20) recently demonstrated frequent and type-specific inactivation of the 14-3-3 gene in small cell lung cancer. In our study, loss of 14-3-3 expression was significantly correlated with high-grade advanced-stage bulky residual tumor and high serum CA125 and high Ki-67 levels, all of these factors represent fundamental difference in pathogenesis in ovarian cancer. Our results, together with previous reports, suggest that the loss of 14-3-3 expression in ovarian cancer may have invasive and progressive characteristics.
Recent study suggests that promoter methylation increases with age in several genes in normal tissues, although the mechanism of age-related methylation is unknown (32, 33) . Several factors may modulate age-related methylation, such as exogenous carcinogens, endogenously generated reactive oxygen species, and genetic differences in individual susceptibility (33) . In our study, 14-3-3 protein expression was decreased in elderly patients by immunohistochemistry. Although age-related methylation of 14-3-3 has not been reported, it is possible that expression of this gene is suppressed by methylation with age, and it may contribute to carcinogenesis in ovarian cancer. In the present study, a clear correlation between aberrant methylation and silencing of 14-3-3 was observed except for one cell line (HTOA) and 2 of 10 primary ovarian cancer tissues, which showed unmethylated patterns despite loss of 14-3-3 expression. These results suggest that DNA methylation-independent mechanism may also be involved in the loss of 14-3-3 expression. Several other ways of gene inactivation such as loss of transcription factor are assumed, and Osada et al. (20) considered that 14-3-3 gene silencing might occur without methylation in only primary tissues. From our results, positive p53 immunoreactivity, which suggests loss of functional p53 protein (34, 35) , seems to contribute to the loss of 14-3-3 expression in primary ovarian tissues. Possible methylationindependent mechanism remains to be elucidated to better understand the regulation of 14-3-3 expression.
In conclusion, aberrant CpG island methylation is an epigenetic change that is largely responsible for silencing of the 14-3-3 gene. Inactivation of 14-3-3 occurs in substantial proportion and may play a role as a potential tumor suppressor gene in epithelial ovarian cancer.
